The role of transporters in drug interactions.

Transport proteins play an important role in the adsorption, distribution and elimination of a wide variety of drugs. Therefore, it is not surprising that transporter-based drug interactions can occur in the clinic. These interactions can lead to changes in toxicity and/or efficacy of the affected drug. Here, we review such interactions and ask if these interactions could have been predicted from in vitro data. Conducting such in vitro-in vivo correlation is important for predicting future transporter-based drug interactions.

[1]  Masahiro Okuda,et al.  Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2 , 2005, Pharmaceutical Research.

[2]  T. Cihlar,et al.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. , 1999, Molecular pharmacology.

[3]  S. Cole,et al.  The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.

[4]  I. Tamai,et al.  Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. , 1990, The Journal of biological chemistry.

[5]  P. Meier,et al.  St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4 , 2000, Clinical pharmacology and therapeutics.

[6]  B. Angelin,et al.  Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine , 1990, Clinical pharmacology and therapeutics.

[7]  Y. Lai,et al.  Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells , 2002, The Journal of Biological Chemistry.

[8]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  Jashvant D Unadkat,et al.  Placental drug transporters. , 2004, Current drug metabolism.

[10]  J. Unadkat,et al.  The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) , 2004, Clinical pharmacology and therapeutics.

[11]  H. Saito,et al.  Molecular cloning and tissue distribution of rat peptide transporter PEPT2. , 1996, Biochimica et biophysica acta.

[12]  P. Sinko,et al.  P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  Y. Sugiyama,et al.  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  A. Somogyi,et al.  Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.

[15]  B. Beermann,et al.  Non-linear elimination and protein binding of probenecid , 2004, European Journal of Clinical Pharmacology.

[16]  Peijin Zhang,et al.  CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS , 2006, Drug Metabolism and Disposition.

[17]  T. Cihlar,et al.  Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. , 2000, Journal of the American Society of Nephrology : JASN.

[18]  G. Mudge,et al.  On the mechanism of action of probenecid on renal tubular secretion. , 1960, Bulletin of the Johns Hopkins Hospital.

[19]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[20]  Cuiping Chen,et al.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[21]  G. Szakács,et al.  MDR3 P-glycoprotein, a Phosphatidylcholine Translocase, Transports Several Cytotoxic Drugs and Directly Interacts with Drugs as Judged by Interference with Nucleotide Trapping* , 2000, The Journal of Biological Chemistry.

[22]  R H Levy,et al.  Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants , 1997, Clinical pharmacology and therapeutics.

[23]  Kari Laine,et al.  Functional role of P‐glycoprotein in the human blood‐placental barrier , 2005, Clinical pharmacology and therapeutics.

[24]  Joanne Wang,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters , 2004 .

[25]  W. Jaross,et al.  Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A , 2001, Journal of cardiovascular pharmacology and therapeutics.

[26]  M. Breen,et al.  pABC11 (Also Known as MOAT-C and MRP5), a Member of the ABC Family of Proteins, Has Anion Transporter Activity but Does Not Confer Multidrug Resistance When Overexpressed in Human Embryonic Kidney 293 Cells* , 1999, The Journal of Biological Chemistry.

[27]  G. Kruh,et al.  The MRP family of drug efflux pumps , 2003, Oncogene.

[28]  D. Markovich,et al.  Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, ßlactam antibiotics and ACE-inhibitors , 1994, Pflügers Archiv.

[29]  P. Neuvonen,et al.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.

[30]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[31]  D. Drayer,et al.  Age and renal clearance of cimetidine , 1982, Clinical pharmacology and therapeutics.

[32]  T. Abe,et al.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[33]  J. Verweij,et al.  Development of Multidrug-Resistance Convertors: Sense or Nonsense? , 2000, Investigational New Drugs.

[34]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[35]  L. Moore,et al.  The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution , 2000 .

[36]  M. Hediger,et al.  Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. , 1995, Biochimica et biophysica acta.

[37]  P. Meier,et al.  The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.

[38]  A. Seelig,et al.  A method to determine the ability of drugs to diffuse through the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Giacomini,et al.  Cloning and functional expression of a human liver organic cation transporter. , 1997, Molecular pharmacology.

[40]  S. Adibi.  The oligopeptide transporter (Pept-1) in human intestine: biology and function. , 1997, Gastroenterology.

[41]  M. Hediger,et al.  Human Intestinal H+/Peptide Cotransporter , 1995, The Journal of Biological Chemistry.

[42]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Paul D. Martin,et al.  Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. , 2003, British journal of clinical pharmacology.

[45]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[46]  O. van Tellingen,et al.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. , 1999, The Journal of clinical investigation.

[47]  J. C. Martin,et al.  (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. , 1995, The Journal of infectious diseases.

[48]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[49]  S. Wright,et al.  Molecular and cellular physiology of renal organic cation and anion transport. , 2004, Physiological reviews.

[50]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[51]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[52]  J. Beijnen,et al.  Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. , 2004, European journal of cancer.

[53]  Y. Sugiyama,et al.  The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. , 2002, Drug metabolism and pharmacokinetics.

[54]  G. Koren,et al.  A model for the prediction of digoxin-drug interactions at the renal tubular cell level. , 1998, Therapeutic drug monitoring.

[55]  John D. Allen,et al.  A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. , 2002, Cancer research.

[56]  L. Mangravite,et al.  Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. , 2003, European journal of pharmacology.

[57]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[58]  M. Kool,et al.  A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome , 1997, Hepatology.

[59]  W. Haefeli,et al.  Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers , 2004, Clinical pharmacology and therapeutics.

[60]  R. Béliveau,et al.  Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. , 1999, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[61]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[62]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[63]  Leslie Z. Benet,et al.  Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay , 2004, Journal of Pharmacology and Experimental Therapeutics.

[64]  P. Hinderling,et al.  Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.

[65]  S. Cole,et al.  Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.

[66]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Nezu,et al.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. , 2000, Biochemical and biophysical research communications.

[68]  H. Saito,et al.  Interaction of β-Lactam Antibiotics with Histidine Residue of Rat H+/Peptide Cotransporters, PEPT1 and PEPT2* , 1998, The Journal of Biological Chemistry.

[69]  F. Russel,et al.  Molecular aspects of renal anionic drug transport. , 2002, Annual review of physiology.

[70]  B. Kuppermann,et al.  Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS , 1997, Annals of Internal Medicine.

[71]  P. A. Rea,et al.  MRP Subfamily Transporters and Resistance to Anticancer Agents , 2001, Journal of bioenergetics and biomembranes.

[72]  R. Traber,et al.  Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. , 2002, Journal of medicinal chemistry.

[73]  N. Klitgaard,et al.  Effect of quinidine on digoxin bioavailability , 2004, European Journal of Clinical Pharmacology.

[74]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[75]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[76]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[77]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[78]  C Roland Wolf,et al.  Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. , 2005, Biochemical pharmacology.

[79]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[80]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.

[81]  K. Audus,et al.  Controlling drug delivery across the placenta. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[82]  H Nakano,et al.  Basal membrane localization of MRP1 in human placental trophoblast. , 2003, Placenta.

[83]  Oliver Burk,et al.  Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.

[84]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[85]  Y. Sawada,et al.  Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. , 2002, Biochemical and biophysical research communications.

[86]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[87]  C. Beglinger,et al.  Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.

[88]  D. Meijer,et al.  Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.

[89]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[90]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[91]  R. Flavell,et al.  Double knockout of the MRP gene leads to increased drug sensitivity in vitro. , 1996, Cancer research.

[92]  F. Marchlinski,et al.  Adenosine as an antiarrhythmic agent. , 1997, The American journal of cardiology.

[93]  L. Mangravite,et al.  Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. , 2003, American journal of physiology. Renal physiology.

[94]  William A. Lee,et al.  Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[95]  F. Loor,et al.  The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions. , 2000, The Journal of antibiotics.

[96]  Ling He,et al.  Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. , 2002, Acta pharmacologica Sinica.

[97]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[98]  Hiroshi Suzuki,et al.  Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)* , 1999, The Journal of Biological Chemistry.

[99]  K. Cundy.  Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir , 1999, Clinical pharmacokinetics.

[100]  G R Lankas,et al.  Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. , 1998, Reproductive toxicology.

[101]  D. Drayer,et al.  Aging and renal clearance of procainamide and acetylprocainamide , 1980, Clinical pharmacology and therapeutics.

[102]  W. Sadee,et al.  An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. , 1998, Cancer research.

[103]  A. Hartmann,et al.  Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.

[104]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[105]  K. Schenck-Gustafsson,et al.  Digoxin‐verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans , 1991, Clinical pharmacology and therapeutics.

[106]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[107]  V. Ganapathy,et al.  Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. , 1997, Biochimica et biophysica acta.

[108]  G R Wilkinson,et al.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[109]  W. Sabbagh,et al.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.

[110]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[111]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[113]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[114]  V. Natarajan,et al.  Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers with Known MDR1 Genotypes , 2004, Therapeutic drug monitoring.

[115]  D. Johnston,et al.  Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. , 2003, Placenta.

[116]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[117]  D. Piwnica-Worms,et al.  Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. , 2000, Biochemical pharmacology.

[118]  Sean Ekins,et al.  Three-Dimensional Quantitative Structure-Permeability Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication , 2001, J. Chem. Inf. Comput. Sci..

[119]  P. Welling,et al.  Pharmacokinetics of cephradine given intravenously with and without probenecid. , 1981, British Journal of Clinical Pharmacology.

[120]  Tsuyoshi Mikkaichi,et al.  The organic anion transporter (OATP) family. , 2004, Drug metabolism and pharmacokinetics.

[121]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[122]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[123]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[124]  D. Keppler,et al.  Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane , 1993, FEBS letters.

[125]  P. Neuvonen,et al.  Itraconazole decreases renal clearance of digoxin. , 1997, Therapeutic drug monitoring.

[126]  C. Sibley,et al.  Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. , 2003, American journal of physiology. Cell physiology.

[127]  S. Bates,et al.  Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1) , 2002, Cancer biology & therapy.

[128]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[129]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[130]  J. S. Wang,et al.  Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[131]  D. Keppler,et al.  Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. , 1996, Cancer research.

[132]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[133]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[134]  S. Herrine,et al.  Severe hepatotoxicity associated with troglitazone. , 1999, Annals of internal medicine.

[135]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[136]  M. Polis,et al.  Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients , 1995, Antimicrobial agents and chemotherapy.

[137]  K. Maeda,et al.  Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[138]  T. Voskoglou-Nomikos,et al.  Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  M Zschiesche,et al.  Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.

[140]  S. Cole,et al.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line , 2008, Cancer Chemotherapy and Pharmacology.

[141]  J. Hitti,et al.  P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[142]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[143]  H. Krum,et al.  Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class , 2003, Drug safety.

[144]  J. Beijnen,et al.  The functional role of P-glycoprotein in the blood-brain barrier. , 1997, Journal of pharmaceutical sciences.

[145]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[146]  G. Bodemar,et al.  Oral absorption of cimetidine and its clearance in patients with renal failure , 1979, European Journal of Clinical Pharmacology.

[147]  E. Randinitis,et al.  Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.

[148]  J. Wijnholds,et al.  The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. , 1999, Cancer research.

[149]  P. Neuvonen,et al.  Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate , 2001, Clinical pharmacology and therapeutics.

[150]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[151]  A. Somogyi,et al.  Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs , 2004, European Journal of Clinical Pharmacology.

[152]  D. Piwnica-Worms,et al.  Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[153]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[154]  Roger L. Nation,et al.  Differential Bidirectional Transfer of Indinavir in the Isolated Perfused Human Placenta , 2005, Antimicrobial Agents and Chemotherapy.

[155]  A. Somogyi,et al.  Pharmacokinetics and Bioavailability of Cimetidine in Gastric and Duodenal Ulcer Patients , 1980, Clinical pharmacokinetics.

[156]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  Hua Yang,et al.  The Binding of Cyclosporin A to Human Plasma: An in Vitro Microdialysis Study , 1996, Pharmaceutical Research.

[158]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[159]  K. Ward,et al.  Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey , 2004, Journal of Pharmacology and Experimental Therapeutics.

[160]  W Vaalburg,et al.  Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.

[161]  G. Sousa,et al.  Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes , 1991, Fundamental & clinical pharmacology.

[162]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[163]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[164]  R. Kim,et al.  P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.